Boronated starburst dendrimer-monoclonal antibody immunoconjugates: evaluation as a potential delivery system for neutron capture therapy.

Boron neutron capture therapy (BNCT) is based on the nuclear capture reaction that occurs when boron-10, a stable isotope, is irradiated with low-energy or thermal neutrons (< or = 0.025 eV) to yield high LET alpha particles and recoiling 7Li nuclei [10B + nth-->[11B]-->4He(alpha) + 7Li + 2.39 MeV]. Approximately 10(9) boron-10 atoms must be delivered to each target cell in order to sustain a lethal 10B(n,alpha)7Li reaction. If MoAbs are to be used for targeting boron-10, then it is essential that they recognize a surface membrane epitope that is highly expressed on tumor cells and that a large number of boron-10 atoms be attached to each antibody molecule. In order to heavily boronate MoAbs, we have utilized starburst dendrimers (SD), which are precise, spherical macromolecules composed of repetitive poly(amidoamino) groups. Second- and fourth-generation dendrimers, having 12 and 48 reactive terminal amino groups and molecular weights of 2414 and 10,632 Da, respectively, were boronated using an isocyanato polyhedral borane, Na(CH3)3NB10H8NCO. The boronated starburst dendrimers (BSD), in turn, were derivatized with m-maleimidobenzoyl N-hydroxysulfosuccinimide ester (sulfo-MBS). The MoAbIB16-6, which is directed against the murine B16 melanoma, was derivatized with N-succinimidyl 3-(2-pyridyldithio)propionate (SPDP). The MBS-derivatized BSD and SPDP-derivatized MoAb were reacted to yield stable immunoconjugates.(ABSTRACT TRUNCATED AT 250 WORDS)

[1]  James R. Dewald,et al.  A New Class of Polymers: Starburst-Dendritic Macromolecules , 1985 .

[2]  R. O'Kennedy,et al.  Bifunctional antibodies: concept, production and applications. , 1990, Biochimica et biophysica acta.

[3]  D. Gabel,et al.  Boronated antibodies for neutron capture therapy. , 1989, Strahlentherapie und Onkologie (Print).

[4]  W. Sweet,et al.  The possible use of neutron-capturing isotopes such as boron 10 in the treatment of neoplasms. II. Computation of the radiation energies and estimates of effects in normal and neoplastic brain. , 1952, The Journal of clinical investigation.

[5]  M. Poznansky,et al.  Antibody-mediated targeting of alpha-1,4-glucosidase-albumin polymers to rat hepatocytes. A model for enzyme therapy. , 1981, The Biochemical journal.

[6]  P. Hersey,et al.  Boronated monoclonal antibodies for potential neutron capture therapy of malignant melanoma and leukaemia. , 1989, Strahlentherapie und Onkologie (Print).

[7]  R. W. Baldwin,et al.  Carrier design: biodistribution of branched polypeptides with a poly(L-lysine) backbone. , 1990, Bioconjugate chemistry.

[8]  R. Barth,et al.  Boron neutron capture therapy of cancer. , 1990, Cancer research.

[9]  R. Barth,et al.  Distinct and Non-Cross-Reactive Epitopes are Recognized on B16 Melanoma by LAK Cells and Anti-B16 Monoclonal Antibodies , 1990, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[10]  R. Paxton,et al.  Carboranyl peptide-antibody conjugates for neutron-capture therapy: preparation, characterization, and in vivo evaluation. , 1992, Bioconjugate chemistry.

[11]  S. Tsing,et al.  Monoclonal antibodies against Trichomonas vaginalis. , 1986, Hybridoma.

[12]  M. Hawthorne,et al.  Conjugation of phenyl isothiocyanate derivatives of carborane to antitumor antibody and in vivo localization of conjugates in nude mice. , 1991, Bioconjugate chemistry.

[13]  M. Hawthorne,et al.  Novel carboranyl amino acids and peptides: reagents for antibody modification and subsequent neutron-capture studies. , 1991, Bioconjugate chemistry.

[14]  D. Tomalia,et al.  Starburst dendrimers. 4. Covalently fixed unimolecular assemblages reiminiscent of spheroidal micelles , 1987 .

[15]  Michael B. Hall,et al.  Dendritic macromolecules: synthesis of starburst dendrimers , 1986 .

[16]  J. Price,et al.  Injection of Cells and Monoclonal Antibodies into Mice: Comparison of Tail Vein and Retroorbital Routes 1 , 1984, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[17]  J. Price,et al.  Phenotypic diversity of murine B16 melanoma detected by anti-B16 monoclonal antibodies. , 1987, Cancer research.

[18]  J. C. Roberts,et al.  Using starburst dendrimers as linker molecules to radiolabel antibodies. , 1990, Bioconjugate chemistry.

[19]  E. Mechetner,et al.  Determination of boron in tissues and cells using direct-current plasma atomic emission spectroscopy. , 1991, Analytical chemistry.

[20]  T. Waldmann,et al.  Monoclonal antibodies in diagnosis and therapy , 1991, Science.

[21]  R. Zamenhof,et al.  Boron Neutron Capture Therapy of Cerebral Gliomas , 1975 .

[22]  W. Hunter,et al.  The labelling of proteins to high specific radioactivities by conjugation to a 125I-containing acylating agent. , 1973, The Biochemical journal.

[23]  R. Barth,et al.  Conjugation, purification and characterization of boronated monoclonal antibodies for use in neutron capture therapy. , 1989, Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al].

[24]  W. E. Carey,et al.  Dicesium N-succinimidyl 3-(undecahydro-closo-dodecaboranyldithio)propionate, a novel heterobifunctional boronating agent. , 1985, Journal of medicinal chemistry.

[25]  R. Barth,et al.  Boron neutron capture therapy: linkage of a boronated macromolecule to monoclonal antibodies directed against tumor-associated antigens. , 1989, Journal of medicinal chemistry.

[26]  Wilbur Ds.  Radiohalogenation of proteins: An overview of radionuclides, labeling methods and reagents for conjugate labeling , 1992 .

[27]  W. E. Carey,et al.  Neutron capture using boronated monoclonal antibody directed against tumor-associated antigens. , 1982, Cancer detection and prevention.

[28]  P. Fraker,et al.  Protein and cell membrane iodinations with a sparingly soluble chloroamide, 1,3,4,6-tetrachloro-3a,6a-diphrenylglycoluril. , 1978, Biochemical and biophysical research communications.

[29]  B. Ward,et al.  Localization of the monoclonal antibody HMFG2 after intravenous and intraperitoneal injection into nude mice bearing subcutaneous and intraperitoneal human ovarian cancer xenografts. , 1987, Cancer research.

[30]  B. Delpech,et al.  In vitro immunological activity of a dextran-boronated monoclonal antibody. , 1989, Strahlentherapie und Onkologie (Print).

[31]  M. Hawthorne,et al.  Neutron-capture therapy of human cancer: in vitro results on the preparation of boron-labeled antibodies to carcinoembryonic antigen. , 1982, Proceedings of the National Academy of Sciences of the United States of America.

[32]  Y. Takeda,et al.  An anti-alpha-fetoprotein antibody-daunorubicin conjugate with a novel poly-L-glutamic acid derivative as intermediate drug carrier. , 1984, Journal of the National Cancer Institute.

[33]  M. Hawthorne,et al.  Neutron-capture therapy of human cancer: in vivo results on tumor localization of boron-10-labeled antibodies to carcinoembryonic antigen in the GW-39 tumor model system. , 1984, Proceedings of the National Academy of Sciences of the United States of America.

[34]  R. Barth,et al.  In Vivo Distribution of Boronated Monoclonal Antibodies and Starburst Dendrimers , 1993 .

[35]  M. Hawthorne.  Biochemical applications of boron cluster chemistry , 1991 .

[36]  J. Murray,et al.  Lack of comparability between binding of monoclonal antibodies to melanoma cells in vitro and localization in vivo. , 1989, Journal of the National Cancer Institute.

[37]  O. H. Lowry,et al.  Protein measurement with the Folin phenol reagent. , 1951, The Journal of biological chemistry.